AMCP opposes Part D changes
The academy explained that these sections would disadvantage Medicare beneficiaries because they would prevent Part D drug plan sponsors from using recognized PBM expertise in their development of formularies.
AMCP has written to House committees on Capitol Hill about changes to the Medicare Part D program and the SCHIP legislation now before the House Energy & Commerce and Ways & Means Committees. In the letters, AMCP noted that it "strongly opposes several sections of HR 3162, the Children's Health and Medicare Protection Act of 2007 that would modify the Medicare Part D drug benefit." The academy explained in the letters that these sections would disadvantage Medicare beneficiaries because they would prevent Part D drug plan sponsors from using recognized PBM expertise in their development of formularies.
